Overview

A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA

Status:
Terminated
Trial end date:
2019-09-26
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and efficacy of baricitinib in participants with primary biliary cholangitis (PBC) who do not respond or are unable to take ursodeoxycholic acid (UDCA).
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company